Literature DB >> 20524085

{2-[(3-Carboxy-1-oxopropyl) amino]-2-deoxy-D-Glucose} suppresses proliferation and induces apoptosis in the human esophageal cancer cell line.

Jing Wu1, Hong Lu, Xiangchun Ling, Canghai Wang, Ji Rui, Aiqin Wang, Liang Qiao.   

Abstract

The aim of this study was to investigate the molecular mechanisms of apoptosis induced by {2-[(3-Carboxy-1-oxopropyl) amino]-2-deoxy-D-Glucose} (COPADG) in the esophageal cancer cell line Eca-109 and to establish a relationship between the rate of apoptosis and Fas and Bcl-2 protein expression. Eca-109 cells were cultured under standard condition. Cell growth was measured by MTT assay. Apoptosis and cell proliferation were determined by flow cytometry. Expressions of apoptosis-regulated genes Fas and Bcl-2 were detected by immunohistochemical methods and image analysis. COPADG dose- and time-dependently inhibited the growth of Eca-109 cells in vitro. Incubation of Eca-109 cells with 40 μmol/l of COPADG for 48 h induced significant apoptosis. After drug treatment, Fas protein expression was increased, while Bcl-2 protein expression was decreased. COPADG is able to induce apoptosis in the esophageal cancer cell line Eca-109. The mechanism of apoptosis in these cells may be related to up-regulation of Fas gene expression and the down-regulation of Bcl-2, which may serve as the experimental evidence for development of new drugs for the non-surgical management of human esophageal cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20524085     DOI: 10.1007/s12032-010-9585-1

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  13 in total

1.  Cisplatin induces fas expression in esophageal cancer cell lines and enhanced cytotoxicity in combination with LAK cells.

Authors:  I Matsuzaki; H Suzuki; M Kitamura; Y Minamiya; H Kawai; J Ogawa
Journal:  Oncology       Date:  2000-11       Impact factor: 2.935

Review 2.  The role of FasL-induced apoptosis in immune privilege.

Authors:  T S Griffith; T A Ferguson
Journal:  Immunol Today       Date:  1997-05

3.  Lack of cell surface Fas/APO-1 expression in pulmonary adenocarcinomas.

Authors:  Y Nambu; S J Hughes; A Rehemtulla; D Hamstra; M B Orringer; D G Beer
Journal:  J Clin Invest       Date:  1998-03-01       Impact factor: 14.808

4.  Prognostic significance of Fas and Fas ligand expressions in human esophageal cancer.

Authors:  M Shibakita; M Tachibana; D K Dhar; T Kotoh; S Kinugasa; H Kubota; R Masunaga; N Nagasue
Journal:  Clin Cancer Res       Date:  1999-09       Impact factor: 12.531

5.  Effects of {2-[(3-carboxy-1-oxoprogy1)amino]-2-deoxy-D-glucose} on human hepatocellular carcinoma cell line.

Authors:  Jing Wu; Wei Kou; Ming-tai Gao; Yong-ning Zhou; Ai-qin Wang; Qun-ji Xue; Liang Qiao
Journal:  Acta Pharmacol Sin       Date:  2005-05       Impact factor: 6.150

6.  Expression of Fas and Fas ligand in esophageal tissue mucosa and carcinomas.

Authors:  Satoru Kase; Mitsuhiko Osaki; Hironobu Adachi; Nobuaki Kaibara; Hisao Ito
Journal:  Int J Oncol       Date:  2002-02       Impact factor: 5.650

7.  Colon carcinoma cells use different mechanisms to escape CD95-mediated apoptosis.

Authors:  U von Reyher; J Sträter; W Kittstein; M Gschwendt; P H Krammer; P Möller
Journal:  Cancer Res       Date:  1998-02-01       Impact factor: 12.701

8.  Loss of Bcl-2 expression in Barrett's dysplasia and adenocarcinoma is associated with tumor progression and worse survival but not with response to neoadjuvant chemoradiation.

Authors:  A A Raouf; D A Evoy; E Carton; E Mulligan; M M Griffin; J V Reynolds
Journal:  Dis Esophagus       Date:  2003       Impact factor: 3.429

9.  Effect of 2-(3-carboxy-1-oxopropyl) amino-2-deoxy-D-glucose on human esophageal cancer cell line.

Authors:  Jing Wu; Hong Lu; Yun Zhou; Liang Qiao; Rui Ji; Ai-Qing Wang; Wei-Min Liu; Qun-Ji Xue
Journal:  World J Gastroenterol       Date:  2004-11-15       Impact factor: 5.742

10.  bcl-2 expression and prognosis in squamous-cell carcinomas of the esophagus.

Authors:  M Sarbia; F Bittinger; R Porschen; P Verreet; P Dutkowski; R Willers; H E Gabbert
Journal:  Int J Cancer       Date:  1996-08-22       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.